📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The briefing book for the Pre-NDA/Pre-BLA meeting with the FDA.
Why it exists. Shortly before filing the marketing application, the sponsor and FDA agree on the format, content, and any outstanding issues of the planned submission, reducing the risk of a Refuse-to-File. This book previews the application.
How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.
Format & governing standard. —
| Field | Value |
|---|---|
| Document ID | MTG-PRENDA |
| Version | 1.0 |
| Status | Final (portfolio) |
| Meeting type | Type B (Pre-NDA) — FDA [MOCK] |
| Compound | GLPI-103 (GLP-1 / Apelin [APJ] receptor dual agonist) |
| Sponsor | Virtual Biopharma Inc. |
| Standard(s) | 21 CFR 312.47 · FDA Formal Meetings Guidance (PDUFA VII) · ICH M4 (CTD) · M8 (eCTD) |
No comments yet. Be the first to say something!
| Confidential |
[MOCK]Briefing document supporting a Pre-NDA meeting to align on the content, format, and organization of the planned NDA, and to resolve outstanding review-readiness questions.
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-30 | Regulatory Affairs | Initial Pre-NDA briefing document |
To confirm that the planned NDA content and format are acceptable to support filing and review, including the adequacy of the efficacy/safety datasets, the integrated summaries, the CMC package, and the proposed labeling and risk-management approach.
Both GLPI-103 formulations were superior to oral semaglutide on HbA1c CFB at Week 52 (IV −0.68%, Oral −0.34%; both p<0.001), with greater weight reduction (−14.5 / −10.3 vs −7.6 kg) and higher responder rates. Safety was class-consistent and gastrointestinal-predominant, with a tolerability trade-off (nausea higher in the IV arm, 32.3% vs 21.4%, p=0.003) managed by titration; 10 SAEs and 2 deaths (none treatment-related); no hepatotoxicity (eDISH) (CSR-301; M2.7.3/2.7.4).
eCTD Modules 1-5: full CTD Module 2 summaries (2.3-2.7), Module 3 (CMC, peptide drug substance + IV/oral products), Module 4 (nonclinical), Module 5 (CSR-301 + integrated summaries ISE-301/ISS-301 + early-phase CSRs); SDTM/ADaM datasets with Define-XML 2.1, ADRG/SDRG, and ARM (M5; DEF-301).
CDISC-conformant SDTM and ADaM, validated (Pinnacle 21-equivalent conformance: 0 errors); reproducible analysis pipeline with reconciliation of all reported figures to source outputs (DEF-301; verification gates).
Sponsor seeks confirmation on Questions 1-6 to finalize the NDA for submission within ~90 days of the meeting.